Guardant Health Gets FDA Panel Recommendation for Cancer-Screening Blood Test

By Ben Glickman

Guardant Health said late Thursday that a regulatory advisory panel had recommended the approval of the company's blood test for cancer screening.

The Palo Alto, Calif.-based diagnostics company said that a panel of the U.S. Food and Drug Administration's Medical Devices Advisory Committee "strongly recommended" regulators approve Guardant's Shield test for colorectal-cancer screening, specifically in adults age 45 and up who are at average risk for disease.

The FDA is expected to make a decision on the product later this year.

Guardant Health shares were temporarily halted Thursday morning as the panel reviewed the company's premarket approval application.

Write to Ben Glickman at [e-mail]

(END) Dow Jones Newswires

05-23-24 1940ET